Hunting for peptide substrates of prolyl oligopeptidase: Classical versus non-classical bioactive peptides

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 3, 2011, Pages 319-326

  Tenorio Laranga, Jofre ^a   Männistö, Pekka T ^a   García Horsman, J Arturo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Neuropeptides; Peptide metabolism; Peptidomics; Prolyl endopeptidase; Prolyl oligopeptidase

Indexed keywords

NEUROPEPTIDE; PEPTIDASE; PEPTIDE; PROLINE; PROLYL ENDOPEPTIDASE;

ARTICLE; HUMAN; PROTEIN FUNCTION;

EID: 79951695462     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152711794653841     Document Type: Article

References (93)

1. Venäläinen, J.I.; Juvonen, R.O.; Männistö, P.T. Evolutionary relationships of the prolyl oligopeptidase family enzymes. Eur. J. Biochem., 2004, 271(13), 2705-2715.
2. Fülöp, V.; Böcskei, Z.; Polgár, L. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell, 1998, 94(2), 161-170.
3. Gomez, S.; Boileau, G.; Zollinger, L.; Nault, C.; Rholam, M.; Cohen, P.Site-specific mutagenesis identifies amino acid residues critical in prohormone processing. EMBO J., 1989, 8(10), 2911-2916.
4. Brakch, N.; Lazar, N.; Panchal, M.; Allemandou, F.; Boileau, G.; Cohen, P.; Rholam, M. The somatostatin-28(1-12)-NPAMAP sequence: an essential helical-promoting motif governing prosomatostatin processing at mono- and dibasic sites. Biochemistry, 2002, 41(5), 1630-1639.
5. Männistö, P.T.; Venäläinen, J.; Jalkanen, A.; García-Horsman, J.A. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect., 2007, 20(5), 293-305.
6. Yoshimoto, T.; Kado, K.; Matsubara, F.; Koriyama, N.; Kaneto, H.; Tsura, D. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J. Pharmacobiodyn., 1987, 10(12), 730-735.
7. García-Horsman, J.A.; Männistö, P.T.; Venäläinen, J.I. On the role of prolyl oligopeptidase in health and disease. Neuropeptides, 2007, 41(1), 1-24.
8. Myöhänen, T.T.; García-Horsman, J.A.; Tenorio-Laranga, J.; Männistö, P.T. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J. Histochem. Cytochem., 2009, 57(9), 831-848.
9. Tenorio-Laranga, J.; Coret-Ferrer, F.; Casanova-Estruch, B.; Burgal, M.; García-Horsman, J.A. Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis. J. Neuroinflammation, 2010, 7(1), 23.
10. Peltonen, I.; Jalkanen, A.J.; Sinervä, V.; Puttonen, K.A.; Männistö, P.T. Different effects of scopolamine and inhibition of prolyl oligopeptidase on mnemonic and motility functions of young and 8- to 9-month-old rats in the radial-arm maze. Basic Clin. Pharmacol. Toxicol., 2010, 106(4), 280-287.
11. Gülpinar, M.A.; Yegen, B.C. The physiology of learning and memory: role of peptides and stress. Curr. Protein Pept. Sci., 2004, 5(6), 457-473.
12. Holzhäuer-Oitzl, M.S.; Boucke, K.; Huston, J.P. Reinforcing properties of substance P in the lateral hypothalamus revealed by conditioned place preference. Pharmacol. Biochem. Behav., 1987, 28(4), 511-515.
13. Ogasawara, T.; Itoh, Y.; Tamura, M.; Ukai, Y.; Yoshikuni, Y.; Kimura, K. NS-3, a TRH-analog, reverses memory disruption by stimulating cholinergic and noradrenergic systems. Pharmacol. Biochem. Behav., 1996, 53(2), 391-399.
14. Pan, Y.F.; Chen, X.R.; Wu, M.N.; Ma, C.G.; Qi, J.S. Arginine vasopressin prevents against Abeta(25-35)-induced impairment of spatial learning and memory in rats. Horm. Behav., 2010, 57(4-5), 448-454.
15. Sprick, U.; Hasenohrl, R.U.; Krauth, J.; Klapdor, K.; Huston, J.P. Effects of chronic substance P treatment and intracranial fetal grafts on learning after hippocampal kainic acid lesions. Peptides, 1996, 17(2), 275-285.
16. Bellemère, G.; Morain, P.; Vaudry, H.; Jégou, S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alphamelanocyte-stimulating hormone breakdown in the rat brain. J. Neurochem., 2003, 84(5), 919-929.
17. Bellemère, G.; Vaudry, H.; Morain, P.; Jégou, S. Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophinreleasing hormone catabolism in the rat brain. J. Neuroendocrinol., 2005, 17(5), 306-313.
18. Toide, K.; Okamiya, K.; Iwamoto, Y.; Kato, T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J. Neurochem., 1995, 65(1), 234-240.
19. Jalkanen, A.J.; Puttonen, K.A.; Venäläinen, J.I.; Sinervä, V.; Mannila, A.; Ruotsalainen, S.; Jarho, E.M.; Wallén, E.A.; Männistö, P.T. Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin. Pharmacol. Toxicol., 2007, 100(2), 132-138.
20. Kaneko, T.; Wood, G.; Crouch, W.L.; Desiderio, D.M. Substance P inactivating enzymes in human cerebrospinal fluid. Peptides, 1994, 15(1), 41-47.
21. Michael-Titus, A.T.; Fernandes, K.; Setty, H.; Whelpton, R. In vivo metabolism and clearance of substance P and co-expressed tachykinins in rat striatum. Neuroscience, 2002, 110(2), 277-286.
22. Morain, P.; Lestage, P.; De Nanteuil, G.; Jochemsen, R.; Robin, J.L.; Guez, D.; Boyer, P.A. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment.Preclinical and clinical studies. CNS Drug Rev., 2002, 8(1), 31-52.
23. Toide, K.; Fujiwara, T.; Iwamoto, Y.; Shinoda, M.; Okamiya, K.; Kato, T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain. Naunyn. Schmiedebergs Arch. Pharmacol., 1996, 353(3), 355-362.
24. Nolte, W.M.; Tagore, D.M.; Lane, W.S.; Saghatelian, A. Peptidomics of prolyl endopeptidase in the central nervous system. Biochemistry, 2009, 48(50), 11971-11981.
25. Mendez, M.; Cruz, C.; Joseph-Bravo, P.; Wilk, S.; Charli, J.L. Evaluation of the role of prolyl endopeptidase and pyroglutamyl peptidase I in the metabolism of LHRH and TRH in brain. Neuropeptides, 1990, 17(2), 55-62.
26. Salers, P.; Ouafik, L.H.; Giraud, P.; Dutour, A.; Maltese, J.Y.; Oliver, C. Evidence for pyroglutamyl peptidase I and prolyl endopeptidase activities in the rat insulinoma cell line RINm 5F: lack of relationship with TRH metabolism. Mol. Cell. Biochem., 1991, 106(1), 15-24.
27. Salers, P.; Ouafik, L.H.; Giraud, P.; Maltese, J.Y.; Dutour, A.; Oliver, C. Ontogeny of prolyl endopeptidase, pyroglutamyl peptidase I, TRH, and its metabolites in rat pancreas. Am. J. Physiol., 1992, 262(6 Pt 1), E845-E850.
28. Shinoda, M.; Toide, K.; Ohsawa, I.; Kohsaka, S. Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid beta protein in NG108-15 cells. Biochem. Biophys. Res. Commun., 1997, 235(3), 641-645.
29. Toide, K.; Shinoda, M.; Fujiwara, T.; Iwamoto, Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol. Biochem. Behav., 1997, 56(3), 427-434.
30. Toide, K.; Shinoda, M.; Iwamoto, Y.; Fujiwara, T.; Okamiya, K.; Uemura, A. A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav. Brain Res., 1997, 83(1-2), 147-151.
31. Walter, R. Partial purification and characterization of post-proline cleaving enzyme: enzymatic inactivation of neurohypophyseal hormones by kidney preparations of various species. Biochim. Biophys. Acta, 1976, 422(1), 138-158.
32. Miura, N.; Shibata, S.; Watanabe, S. Increase in the septal vasopressin content by prolyl endopeptidase inhibitors in rats. Neurosci. Lett., 1995, 196(1-2), 128-130.
33. Tenorio-Laranga, J.; Venäläinen, J.I.; Männistö, P.T.; García-Horsman, J.A. Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J., 2008, 275(17), 4415-4427.
34. Breen, G.; Harwood, A.J.; Gregory, K.; Sinclair, M.; Collier, D.; St Clair, D.; Williams, R.S. Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar Disord., 2004, 6(2), 156-161.
35. Baude, A.; Shigemoto, R. Cellular and subcellular distribution of substance P receptor immunoreactivity in the dorsal vagal complex of the rat and cat: a light and electron microscope study. J. Comp. Neurol., 1998, 402(2), 181-196.
36. Lévesque, M.; Wallman, M.J.; Parent, R.; Sík, A.; Parent, A. Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. Neurosci. Res., 2007, 57(3), 362-371.
37. Cook, L.B.; Hinkle, P.M. Fate of internalized thyrotropin-releasing hormone receptors monitored with a timer fusion protein. Endocrinology, 2004, 145(7), 3095-3100.
38. Sun, Y.; Lu, X.; Gershengorn, M.C. Thyrotropin-releasing hormone receptors -- similarities and differences. J. Mol. Endocrinol., 2003, 30(2), 87-97.
39. Hökfelt, T.; Bartfai, T.; Bloom, F. Neuropeptides: opportunities for drug discovery. Lancet Neurol., 2003, 2(8), 463-472.
40. McGinty, J.F. Co-localization of GABA with other neuroactive substances in the basal ganglia. Prog. Brain Res., 2007, 160, 273-284.
41. Myöhänen, T.T.; Venäläinen, J.I.; García-Horsman, J.A.; Männistö, P.T. Spatial association of prolyl oligopeptidase, inositol 1, 4, 5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: an immunohistochemical colocalization study. Neuroscience, 2008, 153(4), 1177-1189.
42. Schulz, I.; Gerhartz, B.; Neubauer, A.; Holloschi, A.; Heiser, U.; Hafner, M.; Demuth, H.U. Modulation of inositol 1, 4, 5-triphosphate concentration by prolyl endopeptidase inhibition. Eur. J. Biochem., 2002, 269(23), 5813-5820.
43. Lenfant, M.; Wdzieczak-Bakala, J.; Guittet, E.; Prome, J.C.; Sotty, D.; Frindel, E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc. Natl. Acad. Sci. USA, 1989, 86(3), 779-782.
44. Liu, J.M.; Lawrence, F.; Kovacevic, M.; Bignon, J.; Papadimitriou, E.; Lallemand, J.Y.; Katsoris, P.; Potier, P.; Fromes, Y.; Wdzieczak-Bakala, J. The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood, 2003, 101(8), 3014-3020.
45. Wang, D.; Carretero, O.A.; Yang, X.Y.; Rhaleb, N.E.; Liu, Y.H.; Liao, T.D.; Yang, X.P. N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am. J. Physiol. Heart Circ. Physiol., 2004, 287(5), H2099-H2105.
46. Cavasin, M.A. Therapeutic potential of thymosin-beta4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in cardiac healing after infarction. Am. J. Cardiovasc. Drugs, 2006, 6(5), 305-311.
47. Smart, N.; Risebro, C.A.; Melville, A.A.; Moses, K.; Schwartz, R.J.; Chien, K.R.; Riley, P.R. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularisation. Nature, 2007, 445(7124), 177-182.
48. Waeckel, L.; Bignon, J.; Liu, J.M.; Markovits, D.; Ebrahimian, T.G.; Vilar, J.; Mees, B.; Blanc-Brude, O.; Barateau, V.; Le Ricousse-Roussanne, S.; Duriez, M.; Tobelem, G.; Wdzieczak-Bakala, J.; Lévy, B.I.; Silvestre, J.S. Tetrapeptide AcSDKP induces postischemic neovascularization through monocyte chemoattractant protein-1 signaling. Arterioscler. Thromb. Vasc. Biol., 2006, 26(4), 773-779.
49. Azizi, M.; Ezan, E.; Nicolet, L.; Grognet, J.M.; Ménard, J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension, 1997, 30(5), 1015-1019.
50. Azizi, M.; Rousseau, A.; Ezan, E.; Guyene, T.T.; Michelet, S.; Grognet, J.M.; Lenfant, M.; Corvol, P.; Ménard, J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyllysyl-proline. J. Clin. Invest., 1996, 97(3), 839-844.
51. Junot, C.; Gonzales, M.F.; Ezan, E.; Cotton, J.; Vazeux, G.; Michaud, A.; Azizi, M.; Vassiliou, S.; Yiotakis, A.; Corvol, P.; Dive, V. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J. Pharmacol. Exp. Ther., 2001, 297(2), 606-611.
52. Huff, T.; Müller, C.S.; Otto, A.M.; Netzker, R.; Hannappel, E. Beta-thymosins, small acidic peptides with multiple functions. Int. J. Biochem. Cell. Biol., 2001, 33(3), 205-220.
53. Cavasin, M.A.; Rhaleb, N.E.; Yang, X.P.; Carretero, O.A. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac- SDKP. Hypertension, 2004, 43(5), 1140-1145.
54. Myöhänen, T.T.; Tenorio-Laranga, J.; Jokinen, B.; Vázquez-Sánchez, R.; Moreno-Baylach, M.J.; Garcia-Horsman, J.A.; Männistö, P. Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. Br. J. Pharmacol., 2010, (in press).
55. Pfister, R.R.; Haddox, J.L.; Sommers, C.I.; Lam, K.W. Identification and synthesis of chemotactic tripeptides from alkalidegraded whole cornea: a study of N-acetyl-proline-glycine-proline and N-methyl-proline-glycine-proline. Invest. Ophthalmol. Vis. Sci., 1995, 36(7), 1306-1316.
56. Weathington, N.M.; van Houwelingen, A.H.; Noerager, B.D.; Jackson, P.L.; Kraneveld, A.D.; Galin, F.S.; Folkerts, G.; Nijkamp, F.P.; Blalock, J.E. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat. Med., 2006, 12(3), 317-323.
57. Haddox, J.L.; Pfister, R.R.; Muccio, D.D.; Villain, M.; Sommers, C.I.; Chaddha, M.; Anantharamaiah, G.M.; Brouillette, W.J.; DeLucas, L.J. Bioactivity of peptide analogs of the neutrophil chemoattractant, N-acetyl-proline-glycine-proline. Invest. Ophthalmol. Vis. Sci., 1999, 40(10), 2427-2429.
58. O'Reilly, P.; Jackson, P.L.; Noerager, B.; Parker, S.; Dransfield, M.; Gaggar, A.; Blalock, J.E. N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD. Respir. Res., 2009, 10, 38.
59. Gaggar, A.; Jackson, P.L.; Noerager, B.D.; O'Reilly, P.J.; McQuaid, D.B.; Rowe, S.M.; Clancy, J.P.; Blalock, J.E. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J. Immunol., 2008, 180(8), 5662-5669.
60. O'Reilly, P.J.; Hardison, M.T.; Jackson, P.L.; Xu, X.; Snelgrove, R.J.; Gaggar, A.; Galin, F.S.; Blalock, J.E. Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, PGP, from collagen. J. Neuroimmunol., 2009, 217(1-2), 51-54.
61. Brandt, I.; De Vriendt, K.; Devreese, B.; Van Beeumen, J.; Van Dongen, W.; Augustyns, K.; De Meester, I.; Scharpé, S.; Lambeir, A.M. Search for substrates for prolyl oligopeptidase in porcine brain. Peptides, 2005, 26(12), 2536-2546.
62. Che, F.Y.; Lim, J.; Pan, H.; Biswas, R.; Fricker, L.D. Quantitative neuropeptidomics of microwave-irradiated mouse brain and pituitary. Mol. Cell. Proteomics, 2005, 4(9), 1391-1405.
63. Pan, H.; Nanno, D.; Che, F.Y.; Zhu, X.; Salton, S.R.; Steiner, D.F.; Fricker, L.D.; Devi, L.A. Neuropeptide processing profile in mice lacking prohormone convertase-1. Biochemistry, 2005, 44(12), 4939-4948.
64. Tagore, D.M.; Nolte, W.M.; Neveu, J.M.; Rangel, R.; Guzman-Rojas, L.; Pasqualini, R.; Arap, W.; Lane, W.S.; Saghatelian, A. Peptidase substrates via global peptide profiling. Nat. Chem. Biol., 2009, 5(1), 23-25.
65. Tenorio-Laranga, J.; Valero, M.L.; Männistö, P.T.; Sánchez del Pino, M.; García-Horsman, J.A. Combination of snap freezing, differential pH two-dimensional reverse-phase high-performance liquid chromatography, and iTRAQ technology for the peptidomic analysis of the effect of prolyl oligopeptidase inhibition in the rat brain. Anal. Biochem., 2009, 393(1), 80-87.
66. Tinoco, A.D.; Tagore, D.M.; Saghatelian, A. Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform. J. Am. Chem. Soc., 2010, 132(11), 3819-3830.
67. Zhang, X.; Che, F.Y.; Berezniuk, I.; Sonmez, K.; Toll, L.; Fricker, L.D. Peptidomics of Cpe(fat/fat) mouse brain regions: implications for neuropeptide processing. J. Neurochem., 2008, 107(6), 1596-1613.
68. Gygi, S.P.; Rist, B.; Gerber, S.A.; Turecek, F.; Gelb, M.H.; Aebersold, R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol., 1999, 17(10), 994-999.
69. Schulz, I.; Zeitschel, U.; Rudolph, T.; Ruiz-Carrillo, D.; Rahfeld, J.U.; Gerhartz, B.; Bigl, V.; Demuth, H.U.; Rossner, S. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J. Neurochem., 2005, 94(4), 970-979.
70. Liu, L.; Zeng, M.; Stamler, J.S. Hemoglobin induction in mouse macrophages. Proc. Natl. Acad. Sci. USA, 1999, 96(12), 6643-6647.
71. Biagioli, M.; Pinto, M.; Cesselli, D.; Zaninello, M.; Lazarevic, D.; Roncaglia, P.; Simone, R.; Vlachouli, C.; Plessy, C.; Bertin, N.; Beltrami, A.; Kobayashi, K.; Gallo, V.; Santoro, C.; Ferrer, I.; Rivella, S.; Beltrami, C.A.; Carninci, P.; Raviola, E.; Gustincich, S. Unexpected expression of alpha- and beta-globin in mesencephalic dopaminergic neurons and glial cells. Proc. Natl. Acad. Sci. USA, 2009, 106(36), 15454-15459.
72. Richter, F.; Meurers, B.H.; Zhu, C.; Medvedeva, V.P.; Chesselet, M.F. Neurons express hemoglobin alpha- and beta-chains in rat and human brains. J. Comp. Neurol., 2009, 515(5), 538-547.
73. Fruitier-Arnaudin, I.; Cohen, M.; Coitoux, C.; Piot, J.M. In vitro metabolism of LVV-Hemorphin-7 by renal cytosol and purified prolyl endopeptidase. Peptides, 2003, 24(8), 1201-1206.
74. Fukui, K.; Shiomi, H.; Takagi, H.; Hayashi, K.; Kiso, Y.; Kitagawa, K. Isolation from bovine brain of a novel analgesic pentapeptide, neo-kyotorphin, containing the Tyr-Arg (kyotorphin) unit. Neuropharmacology, 1983, 22(2), 191-196.
75. Nyberg, F.; Sanderson, K.; Glämsta, E.L. The hemorphins: a new class of opioid peptides derived from the blood protein haemoglobin. Biopolymers, 1997, 43(2), 147-156.
76. Zhao, Q.; Garreau, I.; Sannier, F.; Piot, J.M. Opioid peptides derived from hemoglobin: hemorphins. Biopolymers, 1997, 43(2), 75-98.
77. Gomes, I.; Grushko, J.S.; Golebiewska, U.; Hoogendoorn, S.; Gupta, A.; Heimann, A.S.; Ferro, E.S.; Scarlata, S.; Fricker, L.D.; Devi, L.A. Novel endogenous peptide agonists of cannabinoid receptors. FASEB J., 2009, 23(9), 3020-3029.
78. He, Y.; Hua, Y.; Liu, W.; Hu, H.; Keep, R.F.; Xi, G. Effects of cerebral ischemia on neuronal haemoglobin. J. Cereb. Blood Flow Metab., 2009, 29(3), 596-605.
79. Gelman, J.S.; Sironi, J.; Castro, L.M.; Ferro, E.S.; Fricker, L.D. Hemopressins and other hemoglobin-derived peptides in mouse brain: comparison between brain, blood, and heart peptidome and regulation in Cpefat/fat mice. J. Neurochem., 2010, 113(4), 871-880.
80. Slemmon, J.R.; Feng, B.; Erhardt, J.A. Small proteins that modulate calmodulin-dependent signal transduction: effects of PEP-19, neuromodulin, and neurogranin on enzyme activation and cellular homeostasis. Mol. Neurobiol., 2000, 22(1-3), 99-113.
81. Di Daniel, E.; Glover, C.P.; Grot, E.; Chan, M.K.; Sanderson, T.H.; White, J.H.; Ellis, C.L.; Gallagher, K.T.; Uney, J.; Thomas, J.; Maycox, P.R.; Mudge, A.W. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol. Cell Neurosci., 2009, 41(3), 373-382.
82. Alexander, K.A.; Cimler, B.M.; Meier, K.E.; Storm, D.R. Regulation of calmodulin binding to P-57.A neurospecific calmodulin binding protein. J. Biol. Chem., 1987, 262(13), 6108-6113.
83. Apel, E.D.; Byford, M.F.; Au, D.; Walsh, K.A.; Storm, D.R. Identification of the protein kinase C phosphorylation site in neuromodulin. Biochemistry, 1990, 29(9), 2330-2335.
84. Baudier, J.; Deloulme, J.C.; Van Dorsselaer, A.; Black, D.; Matthes, H.W. Purification and characterization of a brain-specific protein kinase C substrate, neurogranin (p17). Identification of a consensus amino acid sequence between neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain. J. Biol. Chem., 1991, 266(1), 229-237.
85. Bernay, B.; Gaillard, M.C.; Guryca, V.; Emadali, A.; Kuhn, L.; Bertrand, A.; Detraz, I.; Carcenac, C.; Savasta, M.; Brouillet, E.; Garin, J.; Elalouf, J.M. Discovering new bioactive neuropeptides in the striatum secretome using in vivo microdialysis and versatile proteomics. Mol. Cell. Proteomics, 2009, 8(5), 946-958.
86. Sayah, M.; Fortenberry, Y.; Cameron, A.; Lindberg, I. Tissue distribution and processing of proSAAS by proprotein convertases. J. Neurochem., 2001, 76(6), 1833-1841.
87. Qian, Y.; Devi, L.A.; Mzhavia, N.; Munzer, S.; Seidah, N.G.; Fricker, L.D. The C-terminal region of proSAAS is a potent inhibitor of prohormone convertase 1. J. Biol. Chem., 2000, 275(31), 23596-23601.
88. Kikuchi, K.; Arawaka, S.; Koyama, S.; Kimura, H.; Ren, C.H.; Wada, M.; Kawanami, T.; Kurita, K.; Daimon, M.; Kawakatsu, S.; Kadoya, T.; Goto, K.; Kato, T. An N-terminal fragment of ProSAAS (a granin-like neuroendocrine peptide precursor) is associated with tau inclusions in Pick's disease. Biochem. Biophys. Res. Commun., 2003, 308(3), 646-654.
89. Gelman, J.S.; Fricker, L.D. Hemopressin and other bioactive peptides from cytosolic proteins: are these non-classical neuropeptides? AAPS J., 2010, 12(3), 279-289.
90. Brandt, I.; Gérard, M.; Sergeant, K.; Devreese, B.; Baekelandt, V.; Augustyns, K.; Scharpé, S.; Engelborghs, Y.; Lambeir, A.M. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides, 2008, 29(9), 1472-1478.
91. Di Daniel, E.; Mudge, A.W.; Maycox, P.R. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord., 2005, 7(1), 33-41.
92. Williams, R.S.; Cheng, L.; Mudge, A.W.; Harwood, A.J. A common mechanism of action for three mood-stabilizing drugs. Nature, 2002, 417(6886), 292-295.
93. Jeffery, C.J. Moonlighting proteins. Trends Biochem. Sci., 1999, 24(1), 8-11.